Skip Ribbon Commands
Skip to main content
Assoc Prof Tan Shao Weng Daniel

Assoc Prof Tan Shao Weng Daniel

B.Sc. (Hons), MBBS (London), MRCP (UK), PhD

Senior Consultant

Senior Consultant & Head of Division

National Cancer Centre Singapore

Specialty: Medical Oncology

Clinical Interest: Head & Neck, Thoracic-Oncology

Conditions Treated by this Doctor:
Head and Neck Cancer, Laryngeal Cancer, Larynx Cancer, Lung Cancer, Nasopharyngeal Cancer (Nose Cancer), Thoracic Cancers.

Clinical Appointments

  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Clinical Associate Professor SingHealth Duke-NUS Oncology Academic Clinical Programme


Daniel Shao-Weng Tan, B.Sc. (Hons), MBBS (London), MRCP (UK), PhD, is a Senior Consultant Medical Oncologist at Division of Medical Oncology at National Cancer Centre Singapore, an Associate Professor (Tenure-Track) at Duke-NUS Medical School, and a Senior Clinician-Scientist at Genome Institute of Singapore. Dr. Tan has a specialist interest in thoracic, head and neck oncology and cancer drug development. Dr Tan’s work is focused on addressing the translational gap between basic science and clinical practice – particularly in improving our understanding of the determinants of response and resistance to targeted therapy and immunotherapy.

In recognition of his research, he received the American Society of Clinical Oncology (ASCO) Merit Award twice, an ASCO Young Investigator Award and the SingHealth GCEO Outstanding Clinician-Researcher Award (2016). In 2019, he was awarded the Daniel C. Idhe Lectureship in Medical Oncology from the International Association for Study of Lung Cancer (IASLC) 2019 for his ‘extensive contributions in the lung cancer arena’. He was twice awarded the Clinician-Scientist Award from the National Medical Research Council of Singapore (NMRC). He has published more than 100 peer-reviewed articles, including top tier journals such as The New England Journal of Medicine, The Lancet, Nature, Nature Genetics, Nature Medicine and Journal of Clinical Oncology.

Dr. Tan received undergraduate training at St Bartholomew’s and Royal London Hospitals in the United Kingdom, obtained First Class honours for an Intercalated BSc in Tumor Biology from University College London (UCL), and undertook a postgraduate fellowship in drug development at the Royal Marsden Hospital. In 2017, he completed his PhD in Cancer Biology from Cancer Science Institute, National University of Singapore.


  • B.Sc. (Hons) 
  • MBBS (London) 
  • MRCP (UK) 
  • PhD

Professional Appointments and Committee Memberships

  • Senior Consultant Medical Oncologist at Division of Medical Oncology at National Cancer Centre Singapore
  • Head, Division of Clinical Trials and Epidemiological Sciences
  • Director, Experimental Cancer Therapeutics Unit (Phase I)
  • Associate Professor at Duke-NUS Medical School
  • Senior Clinician-Scientist at Genome Institute of Singapore
  • Adjunct investigator, Singapore Immunology Network
  • Co-lead, Clinical Trials, Singapore Translational Cancer Consortium


  • National Medical Research Council (Singapore) Clinical-Scientist Award – Investigator Category, 2020-2023
  • Daniel C. Idhe Lectureship Award for Medical Oncology (International Association for Study of Lung Cancer), 2019
  • National Medical Research Council (Singapore) Clinician Scientist Award – Investigator Category, 2017-2019
  • SingHealth GCEO Outstanding Clinician-Researcher Award, 2016
  • European Lung Cancer Conference Travel Grant Award (Mentee: David Ng), 2016 
  • SingHealth Publish! Award (Medical Oncology), 2015 
  • European Lung Cancer Conference Travel Grant Award (Mentee: Samuel Ee), 2015 
  • Japan Cancer Association 72nd Annual Meeting Travel Grant Award, 2013 
  • Singapore Health Quality Service Award, 2011 
  • ASCO Cancer Foundation Merit Award (Annual Meeting), 2010 
  • ASCO Cancer Foundation Young Investigator Award, 2009 
  • AACR Scholarship - “Molecular Biology in Clinical Oncology: A Workshop”, 2009 
  • AACR-ECCO-ASCO Fellowship - FLIMS 11 “Methods in Clinical Cancer Research”, 2009 
  • European School of Oncology Travel Grant Award (ECCLU), 2009 
  • ESMO Translational Research Unit Visit Fellowship Institut Jules Bordet, Brussels, Belgium, 2009 
  • American Society of Clinical Oncology (ASCO) Cancer Foundation Merit Award (Molecular Markers Meeting), 2008 
  • Best Poster Award (33rd ESMO Congress), 2008 
  • European Society of Medical Oncology (ESMO) Congress Travel Grant Award, 2008 
  • National Medical Research Council Fellowship Award, Awarded by Ministry of Health, Singapore, Clinical Fellowship to the Drug Development Unit, Royal Marsden Hospital, UK, 2008 
  • Singhealth Talent Development Fund Award, 2008 
  • Best Service Award - Medical Officer (Nov 06 to Apr 07), Singapore General Hospital, 2007 
  • Turnbull Prize in Pathology, St. Bartholomew’s and the Royal London Hospital School of Medicine and Dentistry, 2000 
  • Practical Project Prize (For Best B.Sc. Dissertation), University College London, 1998

Research Interests

  • Drug development in phase I trials


  • Chen JB, Zhang T, Yang HC, et al. Tan DSW*, Hillmer AM*, Zhai WW* Genomic landscape and ethnic specificity of lung adenocarcinoma in Asia. Nature Genetics accepted. [JIF 27.125]
  • Tan DSW*, Leighl NB, Riely G, et al. Phase 1 results of a multicentre, open-label study of nazartinib (EGF816) in adult patients with EGFR-mutant NSCLC. The Lancet Respiratory Medicine accepted. [JIF 22.992]
  • Tan WL#, Chua KLM#, Lin CC,. et al., Tan DSW*, Yang F. Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer. Journal of Thoracic Oncology, accepted [JIF 12.46]
  • Felip E, de Braud F, Maur M, et al., Tan DSW. Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC. Journal of Thoracic Oncology, Articles in Press. [JIF 12.46]
  • Lai GGY, Lim TH, Lim J, et al., Tan DSW. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2019 Jan 24:JCO1800177. doi: 10.1200/JCO.18.00177 [JIF: 26.3]
  • Wu YL, Zhang L, Kim DW, et al., Tan DSW. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J Clin Oncol. Aug 2018. doi: 10.1200/JCO.2108.77.7326 [JIF 26.3]
  • Nahar R, Zhai WW, Zhang T, et al., Tan DSW*. Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. 9 (1):216 Nature Communications 2018
  • Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. (2017) Nat Rev Clin Oncol. Nov 28. doi: 10.1038/nrclinonc.2017.188. [Epub ahead of print]
  • Lau KW, Seng C, Lim TKH, Tan DSW. Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer. (2017) Ann Transl Med. Sep;5(18):372.
  • Tan DSW, Chong FT, Leong HS, et al. Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nat Med. 2017 Sep 18. doi: 10.1038/nm.4401. 

Research Trials

  • A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer (DT), 2015 
  • A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer 
  • An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib (DT), 2015 
  • A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive- Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy (Dlim), 2015 
  • A phase I dose finding study of oral LTT462 in adult patients with advanced solid tumors harboring MAPK pathway alterations, 2016 
  • A Phase Ib/II Multi-centre, Randomized, Open-label Trial to Compare MSC2156119J combined with Gefitinib Versus Chemotherapy as Second Line Treatment in Subjects with MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First Line Gefitinib, 2013 
  • A phase I, multi-center, open label dose escalation and expansion study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFR-mut solid malignancies, 2014 
  • A Phase Ib open-label clinical trial of once daily oral treatment of afatinib plus weekly intravenous infusion of BI 836845 in patients with EGFR mutant non-small cell lung cancer with progression following prior EGFR tyrosine kinase inhibitors, 2014